Key Takeaways
- Novo Nordisk (NVO) CSO Martin Holst Lange believes the company's next-generation drug, CagriSema, has untapped weight loss potential beyond the 23% reduction observed in recent Phase III trials.
- The European Union has moved to freeze the ratification of the "Turnberry Agreement" with the United States, citing "customs chaos" and legal uncertainty following new 15% global tariffs from the Trump administration.
- The European Commission raised approximately €6.09 billion through a triple-tranche bond auction, with yields for 2030 and 2038 maturities falling significantly compared to previous sales.
- Russia's Rosatom has formally offered to build a nuclear power plant in Serbia, intensifying a geopolitical bidding war as the Balkan nation also considers a partnership with France’s EDF.
Novo Nordisk Eyes Superior Efficacy for CagriSema
Novo Nordisk (NVO) Chief Scientific Officer Martin Holst Lange stated on Monday that the company assumes there is further weight loss potential to be unlocked with CagriSema. This optimism follows headline results from the REDEFINE 4 trial, where the drug—a combination of semaglutide and cagrilintide—achieved a 23% weight loss over 84 weeks.
The company is currently exploring higher-dose combinations and longer trial durations to determine the drug's ultimate efficacy ceiling. CagriSema is positioned as a critical successor to Wegovy, aimed at defending market share against Eli Lilly (LLY), whose competing treatment Zepbound has shown high efficacy in similar patient populations.
EU Halts US Trade Deal Amid Tariff Volatility
The European Parliament’s trade chief, Bernd Lange, proposed an immediate freeze on the approval process for the Turnberry Agreement, a major trade deal intended to stabilize transatlantic relations. The move comes in response to President Donald Trump’s decision to hike global tariffs to 15% and a subsequent U.S. Supreme Court ruling that struck down certain emergency tariff powers.
Lange characterized the current situation as "pure customs chaos," noting that the legal basis for the agreement has shifted fundamentally. The EU is demanding a comprehensive legal assessment and clear commitments from Washington before proceeding with any legislative work on the deal, which was originally slated for ratification by March.
Mixed Yields in Major EU Bond Auctions
The European Union successfully auctioned three separate bond tranches on Monday, totaling over €6 billion in issuance. The €2.176 billion sale of 2030 bonds saw the average yield drop to 2.454%, down from 2.805% in the previous auction, reflecting strong investor appetite despite broader market volatility.
In contrast, the €1.986 billion auction of 2028 bonds saw a slight yield increase to 2.185% from a previous 2.128%. The longest maturity offered, a €1.93 billion tranche of 2038 bonds, cleared at an average yield of 3.319%, significantly lower than the 3.489% recorded in the prior sale, with a bid-to-cover ratio of 1.16x.
Rosatom Challenges Western Influence in Serbian Energy
Alexey Likhachev, head of the Russian state nuclear corporation Rosatom, announced that Russia is ready to provide Serbia with a nuclear power plant project based on Russian technology. The offer includes the possibility of forming an international consortium to manage the project, providing Serbia with flexibility in how it develops its first nuclear facility.
The proposal follows Serbia's recent decision to lift a 35-year moratorium on nuclear energy to meet growing demand driven by AI development and decarbonization goals. While Rosatom is a global leader with 30 projects currently under construction, Serbia is also in active negotiations with the French energy giant EDF, signaling a strategic competition between Eastern and Western technology providers.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.